SCHEMBL11946144

SCHEMBL11946144

CN1CCN(c2cnn(-c3cc(F)cc(F)c3)c(=O)c2OC[C@H]2C[C@@H]2CF)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ ALDH1A1 P00352 8/20 0.35
▸ CYP1A2 P05177 6/20 0.35
▸ HSD17B10 Q99714 6/20 0.35
▸ CASP1 P29466 6/20 0.35
▸ CASP7 P55210 6/20 0.35
▸ USP2 O75604 6/20 0.35
▸ HIF1A Q16665 6/20 0.35
▸ CYP2C9 P11712 4/20 0.35
▸ SLC2A1 P11166 2/20 0.34
▸ SLC2A3 P11169 2/20 0.34
▸ GLA P06280 1/20 0.33
▸ CYP3A4 P08684 6/20 0.33
▸ MAPK1 P28482 2/20 0.33
▸ TP53 P04637 2/20 0.33
▸ NPSR1 Q6W5P4 2/20 0.33
▸ CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11946141 0.92 POLB (0.39) POLBSMN1; SMN2LMNAKMT2AALDH1A1
SCHEMBL11946143 0.91 POLB (0.39) POLBSMN1; SMN2LMNAKMT2AALDH1A1
SCHEMBL11946142 0.89 POLB (0.37) POLBSMN1; SMN2LMNAKMT2AALDH1A1
SCHEMBL11946145 0.89 CYP3A4 (0.34) POLBLMNAKMT2AALDH1A1CYP1A2
SCHEMBL11946148 0.87 POLB (0.36) POLBALDH1A1SLC2A1SLC2A3CYP3A4
SCHEMBL11946146 0.82 MAPT (0.42) POLBLMNAKMT2AALDH1A1CYP3A4
SCHEMBL11946149 0.81 MAPT (0.35) POLBALDH1A1SLC2A1SLC2A3CYP3A4
SCHEMBL17058088 0.80 ALDH1A1 (0.35) LMNAKMT2AALDH1A1CYP1A2HSD17B10
SCHEMBL11946147 0.79 POLB (0.37) POLBLMNAALDH1A1CYP3A4MAPK1
SCHEMBL11946125 0.78 POLB (0.40) POLBSMN1; SMN2LMNAKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2137179-B1 PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS MERCK SHARP & DOHME (US) 2015-09-02 — — EP disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA POLB 1088/4885SMN1; SMN2 3911/4885LMNA 929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback